D.E. Shaw & Co’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

D.E. Shaw & Co’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$757K	Buy	11,416 +1,180	+12%	+$69.1K	﹤0.01%	3943
2026 Q1	$554K	Buy	+10,236	New	+$571K	﹤0.01%	3800
2025 Q2	–	Sell	-7,737	Closed	-$339K	–	4781
2025 Q1	$339K	Sell	7,737 -700	-8%	-$30.9K	﹤0.01%	3711
2024 Q4	$363K	Buy	8,437 +1,899	+29%	+$86.3K	﹤0.01%	3794
2024 Q3	$290K	Buy	+6,538	New	+$280K	﹤0.01%	3992
2020 Q2	–	Sell	-16,900	Closed	-$610K	–	4294
2020 Q1	$610K	Hold	16,900	–	–	﹤0.01%	3097
2019 Q4	$772K	Hold	16,900	–	–	﹤0.01%	3156
2019 Q3	$601K	Hold	16,900	–	–	﹤0.01%	3123
2019 Q2	$673K	Buy	+16,900	New	+$665K	﹤0.01%	2912

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

D.E. Shaw & Co's XPH Position: Q2 2026 in Review

D.E. Shaw & Co increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 12% in Q2 2026, buying an estimated $69.1K and bringing the position to 11,416 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

D.E. Shaw & Co first reported a position in XPH in Q2 2019 and has held it in 9 quarters since. The position peaked at $772K in Q4 2019. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

D.E. Shaw & Co held 11,416 shares of State Street SPDR S&P Pharmaceuticals ETF worth $757K as of Q2 2026.
D.E. Shaw & Co bought 1,180 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $69.1K.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3943 holding.
D.E. Shaw & Co first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2019 and has held it in 9 quarters since.
D.E. Shaw & Co's State Street SPDR S&P Pharmaceuticals ETF position peaked at $772K in Q4 2019.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.